home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Petros Pharmaceuticals, Inc. - Common Stock (NQ:PTPI)

0.0664 UNCHANGED

Last Price Updated: 4:00 PM EDT, May 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Petros Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

On Wednesday, there are stocks with unusual volume. Let's take a look. ↗

February 19, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session.

Via Chartmill

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

February 18, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.

Via Chartmill

Crude Oil Gains 1.5%; Fluor Shares Plunge Following Downbeat Earnings ↗

February 18, 2025

Via Benzinga

Unusual volume stocks in Tuesday's session ↗

February 18, 2025

Let's have a look at the stocks with an unusual volume in today's session.

Via Chartmill

Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules

January 07, 2025

Via ACCESSWIRE

Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”

December 19, 2024

Via ACCESSWIRE

Which stocks are moving on Tuesday? ↗

February 18, 2025

Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

Tuesday's session: gap up and gap down stocks ↗

February 18, 2025

In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

US Stocks Mixed; NY State Business Activity Rises In February ↗

February 18, 2025

Via Benzinga

Wondering what's happening in today's pre-market session? ↗

February 18, 2025

The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants

February 18, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 18, 2025

Via Benzinga

What's going on in today's session ↗

February 14, 2025

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Via Chartmill

Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗

December 19, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 18, 2024

Via Benzinga

Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket ↗

December 18, 2024

Via Benzinga

Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually

December 17, 2024

Via ACCESSWIRE

Why Mitek Systems Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket ↗

December 17, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 25, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 23, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 15, 2024

Via Benzinga

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

September 11, 2024

Via ACCESSWIRE

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 03, 2024

Via ACCESSWIRE

PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗

August 16, 2024

PTPI stock results show that Petros Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

July 29, 2024

Via ACCESSWIRE

Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance

July 16, 2024

Via ACCESSWIRE

EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says ↗

June 17, 2024

Petros Pharmaceuticals specializes in men's health therapeutics. President Fady Boctor discusses the company's strategy to make key prescription medications. Petros is poised to expand within the $66.5...

Via Benzinga

Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 13, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

June 13, 2024

Via Benzinga

Why Broadcom Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket ↗

June 13, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com